Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biohaven Pharmaceutical Holding Co Ltd.

20.37
+1.699.05%
Post-market: 20.500.1300+0.64%19:18 EDT
Volume:2.10M
Turnover:41.81M
Market Cap:2.08B
PE:-2.20
High:20.51
Open:18.99
Low:18.50
Close:18.68
Loading ...

Biohaven outcome ‘fundamental net positive’ for Scholar Rock, says JPMorgan

TIPRANKS
·
26 Nov 2024

Biohaven Ltd : RBC Cuts Target Price to $58 From $66

THOMSON REUTERS
·
25 Nov 2024

RBC Cuts Price Target on Biohaven to $58 From $66, Maintains Outperform Rating

MT Newswires Live
·
25 Nov 2024

Biohaven falls -9.0%

TIPRANKS
·
25 Nov 2024

Biohaven Shares Dip 0.8% as Spinal Muscular Atrophy Drug Fails to Meet Study Goal

THOMSON REUTERS
·
25 Nov 2024

Scholar Rock Holding Shares Jump 37.5% After Rival Biohaven's Rare Genetic Disorder Drug Fails Trial Goal

THOMSON REUTERS
·
25 Nov 2024

Sector Update: Health Care Stocks Edge Higher Premarket Monday

MT Newswires Live
·
25 Nov 2024

BUZZ-Biohaven falls as genetic disorder drug fails to meet goal in late-stage study

Reuters
·
25 Nov 2024

Biohaven Says Potential Neurodegenerative Disease Treatment Failed to Achieve Statistical Significance; Shares Fall Pre-Bell

MT Newswires Live
·
25 Nov 2024

Biohaven's spinal muscular atrophy drug fails to meet main goal in study

Reuters
·
25 Nov 2024

BRIEF-Biohaven Provides Update On Taldefgrobep Alfa Development Program

Reuters
·
25 Nov 2024

Biohaven Shares Fall 12.3% Premarket as Sma Treatment Did Not Show Statistically Significant Difference on Primary Outcome in Trial

THOMSON REUTERS
·
25 Nov 2024

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

THOMSON REUTERS
·
25 Nov 2024

Biohaven Ltd - Taldefgrobep Well-Tolerated With No Treatment-Related Saes

THOMSON REUTERS
·
25 Nov 2024

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

PR Newswire
·
25 Nov 2024

Here are 4 biotech stocks that could get a boost from Trump's new regulatory climate

Dow Jones
·
23 Nov 2024

Here are 4 biotech stocks that could get a boost from Trump's new regulatory climate

Dow Jones
·
20 Nov 2024

Biotech-stock investing has one tough test for success - and it's about to get easier

Dow Jones
·
18 Nov 2024

Biohaven Ltd. (BHVN) Receives a Buy from Morgan Stanley

TIPRANKS
·
15 Nov 2024

Biohaven Price Target Maintained With a $59.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Nov 2024